Effects of cholinesterase inhibition on attention and working memory in Lewy body dementias.
Sean James FallonOlivia PlantYounes A TabiSanjay G ManoharMasud HusainPublished in: Brain communications (2023)
Cholinesterase inhibitors are frequently used to treat cognitive symptoms in Lewy body dementias (Parkinson's disease dementia and dementia with Lewy bodies). However, the selectivity of their effects remains unclear. In a novel rivastigmine withdrawal design, Parkinson's disease dementia and dementia with Lewy bodies patients were tested twice: once when taking rivastigmine as usual and once when they had missed one dose. In each session, they performed a suite of tasks (sustained attention, simple short-term recall, distractor resistance and manipulating the focus of attention) that allowed us to investigate the cognitive mechanisms through which rivastigmine affects attentional control. Consistent with previous literature, rivastigmine withdrawal significantly impaired attentional efficacy (quicker response latencies without a change in accuracy). However, it had no effects on cognitive control as assessed by the ability to withhold a response (inhibitory control). Worse short-term memory performance was also observed when patients were OFF rivastigmine, but these effects were delay and load independent, likely due to impaired visual attention. In contrast to previous studies that have examined the effects of dopamine withdrawal, cognitively complex tasks requiring control over the contents of working memory (ignoring, updating or shifting the focus of attention) were not significantly impaired by rivastigmine withdrawal. Cumulatively, these data support that the conclusion that cholinesterase inhibition has relatively specific and circumscribed-rather than global-effects on attention that may also affect performance on simple short-term memory tasks, but not when cognitive control over working memory is required. The results also indicate that the withdrawal of a single dose of rivastigmine is sufficient to reveal these impairments, demonstrating that cholinergic withdrawal can be an informative clinical as well as an investigative tool.
Keyphrases
- working memory
- transcranial direct current stimulation
- mild cognitive impairment
- attention deficit hyperactivity disorder
- end stage renal disease
- ejection fraction
- parkinson disease
- cognitive impairment
- chronic kidney disease
- newly diagnosed
- systematic review
- peritoneal dialysis
- prognostic factors
- magnetic resonance
- gene expression
- magnetic resonance imaging
- patient reported outcomes
- cognitive decline
- dna methylation
- physical activity
- genome wide
- metabolic syndrome
- deep brain stimulation
- deep learning
- depressive symptoms
- big data